Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each adding about 1.2%.
The iShares Biotechnology ETF (IBB) increased 0.2%.
In sector news, Boston Scientific (BSX) shares gained 1.9% after the company said Tuesday a trial evaluating its investigational catheter for treating severe coronary artery disease met primary safety and effectiveness endpoints.
Tiziana Life Sciences' (TLSA) intranasal foralumab showed good long-term tolerability and fatigue improvement in an expanded access program involving 14 patients with non-active secondary progressive multiple sclerosis based on updated clinical data, the company said. Its shares rose 3%.
UroGen Pharma's (URGN) investor event reinforced the commercial thesis for Zusduri in low-grade intermediate-risk non-muscle invasive bladder cancer, with a physician panel suggesting that peers may face tough competition unless they can offer overwhelmingly better efficacy, Oppenheimer said in a note. UroGen shares were down 0.8%.
MetaVia (MTVA) shares surged 64% Tuesday, a day after the company said three late-breaking abstracts highlighting its cardiometabolic assets were accepted for poster presentations at the American Diabetes Association's 2026 Scientific Sessions.